Logo image of RNAZ

TRANSCODE THERAPEUTICS INC (RNAZ) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RNAZ - US89357L5012 - Common Stock

9.51 USD
-0.91 (-8.73%)
Last: 12/12/2025, 8:00:29 PM
9.4 USD
-0.11 (-1.16%)
After Hours: 12/12/2025, 8:00:29 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RNAZ. RNAZ was compared to 529 industry peers in the Biotechnology industry. RNAZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RNAZ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RNAZ has reported negative net income.
In the past year RNAZ has reported a negative cash flow from operations.
RNAZ had negative earnings in each of the past 5 years.
RNAZ had a negative operating cash flow in each of the past 5 years.
RNAZ Yearly Net Income VS EBIT VS OCF VS FCFRNAZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -297.95%, RNAZ is not doing good in the industry: 93.41% of the companies in the same industry are doing better.
RNAZ has a Return On Equity of -400.64%. This is in the lower half of the industry: RNAZ underperforms 75.14% of its industry peers.
Industry RankSector Rank
ROA -297.95%
ROE -400.64%
ROIC N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAZ Yearly ROA, ROE, ROICRNAZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNAZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAZ Yearly Profit, Operating, Gross MarginsRNAZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, RNAZ has more shares outstanding
The number of shares outstanding for RNAZ has been increased compared to 5 years ago.
There is no outstanding debt for RNAZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNAZ Yearly Shares OutstandingRNAZ Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
RNAZ Yearly Total Debt VS Total AssetsRNAZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

RNAZ has an Altman-Z score of -15.88. This is a bad value and indicates that RNAZ is not financially healthy and even has some risk of bankruptcy.
RNAZ's Altman-Z score of -15.88 is on the low side compared to the rest of the industry. RNAZ is outperformed by 81.36% of its industry peers.
There is no outstanding debt for RNAZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.88
ROIC/WACCN/A
WACCN/A
RNAZ Yearly LT Debt VS Equity VS FCFRNAZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 5.27 indicates that RNAZ has no problem at all paying its short term obligations.
RNAZ has a Current ratio (5.27) which is in line with its industry peers.
A Quick Ratio of 5.27 indicates that RNAZ has no problem at all paying its short term obligations.
With a Quick ratio value of 5.27, RNAZ perfoms like the industry average, outperforming 58.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.27
Quick Ratio 5.27
RNAZ Yearly Current Assets VS Current LiabilitesRNAZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.05% over the past year.
EPS 1Y (TTM)99.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
RNAZ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 147.39% yearly.
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%

3.3 Evolution

RNAZ Yearly Revenue VS EstimatesRNAZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2028 2029 2030 10M 20M 30M 40M 50M
RNAZ Yearly EPS VS EstimatesRNAZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -200K -400K -600K -800K -1M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RNAZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNAZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAZ Price Earnings VS Forward Price EarningsRNAZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAZ Per share dataRNAZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K

4.3 Compensation for Growth

A more expensive valuation may be justified as RNAZ's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

RNAZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TRANSCODE THERAPEUTICS INC

NASDAQ:RNAZ (12/12/2025, 8:00:29 PM)

After market: 9.4 -0.11 (-1.16%)

9.51

-0.91 (-8.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/amc
Earnings (Next)N/A N/A
Inst Owners2.78%
Inst Owner Change-50.92%
Ins Owners0.14%
Ins Owner Change0%
Market Cap8.75M
Revenue(TTM)N/A
Net Income(TTM)-24.63M
Analysts82.86
Price TargetN/A
Short Float %4.3%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)-1462.72
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-15.61
FCFYN/A
OCF(TTM)-15.6
OCFYN/A
SpS0
BVpS6.68
TBVpS6.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -297.95%
ROE -400.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.27
Quick Ratio 5.27
Altman-Z -15.88
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)51.71%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.25%
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%
EBIT growth 1Y17.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.28%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSCODE THERAPEUTICS INC / RNAZ FAQ

What is the ChartMill fundamental rating of TRANSCODE THERAPEUTICS INC (RNAZ) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RNAZ.


What is the valuation status of TRANSCODE THERAPEUTICS INC (RNAZ) stock?

ChartMill assigns a valuation rating of 1 / 10 to TRANSCODE THERAPEUTICS INC (RNAZ). This can be considered as Overvalued.


What is the profitability of RNAZ stock?

TRANSCODE THERAPEUTICS INC (RNAZ) has a profitability rating of 0 / 10.


What is the earnings growth outlook for TRANSCODE THERAPEUTICS INC?

The Earnings per Share (EPS) of TRANSCODE THERAPEUTICS INC (RNAZ) is expected to grow by 99.7% in the next year.